Clinical Scorecard: Inhibition of Proteasome Activity Triggers a BRCAness Phenotype and Enhances Sensitivity to PARP Inhibitors in HR-Proficient Ovarian Cancer Models
At a Glance
Category
Detail
Condition
Ovarian Cancer
Key Mechanisms
Proteasome inhibition induces a BRCAness phenotype, impairing homologous recombination repair and enhancing sensitivity to PARP inhibitors.
Target Population
Patients with homologous recombination–proficient (HRP) ovarian cancer.
Care Setting
Oncology clinical research.
Key Highlights
Proteasome inhibitors, particularly ixazomib citrate, sensitize HRP ovarian cancer models to PARP inhibition.
Ixazomib citrate disrupts RAD51 recruitment to DNA damage sites, inducing a functional HRD-like state.
Combination therapy with ixazomib citrate and olaparib significantly suppresses tumor growth in xenograft models.
Proteasome inhibition increases tumor-surface MHC class I expression, enhancing susceptibility to CD8+ T-cell-mediated killing.
Guideline-Based Recommendations
Diagnosis
Assess homologous recombination proficiency in ovarian cancer patients.
Management
Consider proteasome inhibitors as a strategy to sensitize HRP ovarian cancer to PARP inhibitors.
Monitoring & Follow-up
Monitor tumor response to combination therapy in clinical settings.
Risks
Evaluate potential immune-related effects and cytotoxicity associated with combination therapy.
Patient & Prescribing Data
Patients with high-grade serous ovarian cancer classified as HRP.
Ixazomib citrate may enhance the efficacy of PARP inhibitors in HRP ovarian cancer.
Clinical Best Practices
Utilize drug repurposing strategies to identify novel sensitizing agents for PARP inhibitors.
Conduct further validation of findings in preclinical and clinical models.
